Navigation Links
Vermillion Announces Receipt of NASDAQ Panel Decision
Date:9/25/2008

FREMONT, Calif., Sept. 25 /PRNewswire-FirstCall/ -- Vermillion, Inc. (Nasdaq: VRML), a molecular diagnostics company, today announced that it has received notification from The NASDAQ Stock Market LLC that the NASDAQ Listing Qualifications Panel has determined to delist the Company's securities from The NASDAQ Capital Market, effective as of the open of business on Thursday, September 25, 2008. The delisting is the result of the Company's noncompliance with the minimum stockholders' equity requirement for continued listing on The NASDAQ Capital Market, as set forth in Marketplace Rule 4310(c)(3).

The Company has been advised that its securities are immediately eligible for quotation in the Pink Sheets, an electronic quotation service for securities traded over-the-counter, effective as of the open of business on Thursday, September 25, 2008. The Company's shares will continue to trade under the symbol VRML. In addition, the Company has been advised that a Market Maker is filing the necessary application with the Financial Industry Regulatory Authority ("FINRA") to quote the securities and as a result we anticipate in the near future that the Company will be quoted on the Over-the-Counter Bulletin Board (the "OTCBB").

About Vermillion

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Vermillion is based in Fremont, California. Additional information about Vermillion can be found on the Web at

SOURCE Vermillion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vermillion and Stanford Scientists Receive Best Research Award From the PAD Coalition
2. Vermillion Retains ThinkPanmure to Assist in the Evaluation of Potential Strategic Alternatives
3. Vermillion to Host Live Roundtable Discussion With Principal Investigator of OVA1(TM) Submission
4. Vermillion Announces First Quarter 2008 Financial Results and Business Progress
5. Vermillions Roundtable Teleconference Highlights Peripheral Artery Disease Diagnostic Program; Features Commentary from Vascular Medicine Expert
6. Vermillion Announces Appointment of John Hamilton to Board of Directors
7. Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease
8. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
9. Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones
10. Vermillion Announces Effectiveness of Reverse Stock Split
11. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... , July 1, 2015  Axovant Sciences Ltd. ... on the treatment of dementia, today announced that ... July 22 at 5:45 p.m. EDT following its ... Association International Conference 2015 (AAIC). ... , Dr. Lawrence Friedhoff , Chief ...
(Date:7/1/2015)... ... ... A newly launched business plan contest will ask startup companies from around the ... R&D. The Pistoia Alliance President’s Startup Challenge 2015 will see small and medium enterprises ... mentorship from a senior industry figure drawn from the Pistoia Alliance membership. , The ...
(Date:7/1/2015)... , ... July 01, 2015 , ... Apex Therapeutics announced ... International Convention in Philadelphia, PA. , The presentation took place on Tuesday, ... the plans for the development of APX3330 for the treatment of pancreatic cancer. ...
(Date:7/1/2015)... NEW YORK , July 1, 2015 /PRNewswire/ ... G ), a global leader in designing, ... the Aecus Innovation Award in recognition of their ... operational efficiencies in UCB,s global business services (GBS) ... acknowledge service providers and clients that work together ...
Breaking Biology Technology:Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5
... Joins Company from Roche Diagnostics -, SUNNYVALE, ... privately held biotechnology company, today announced that Linda,McAllister, ... as Vice,President of Diagnostics, a new position. Dr. ... diagnostics industry as well as in,clinical medicine and ...
... patients through use ... of combined diagnostic and therapeutic -, TORONTO, March ... new findings were presented showing a,mortality reduction in endotoxemic ... Assay, the only FDA cleared,diagnostic for the measurement of ...
... March 18 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,(TSX: ONC, ... been,granted U.S. Patent 7,344,711 entitled "Use of Adenoviruses ... claims describe methods of treating,cancer using adenoviruses that ... have an activated Ras pathway., "This patent ...
Cached Biology Technology:Dr. Linda McAllister Joins Arbor Vita Corporation as Vice President of Diagnostics 2Spectral announces new findings on the effectiveness of EAA(TM)/Toraymyxin(TM) at the 28th International Symposium on Intensive Care and Emergency Medicine 2Oncolytics Biotech Inc. Announces Issuance of 26th U.S. Patent 2
(Date:6/29/2015)... , June 24, 2015 ... of the "Latin America Biomedical Sensors Market - ... offering. The Latin America Biomedical Sensors market ... CAGR of 2.04% over the period 2014-2020 ... adaptable to the genetic formulation of each individual. These ...
(Date:6/25/2015)... 25, 2015  Imagine a tool specifically designed to ... happier life. That,s exactly what USANA,s True Health ... cutting-edge, portable health program provides a personalized approached to ... improve your lifestyle and nutrition. At ... Wednesday night, USANA,s THA was honored with the Industry ...
(Date:6/24/2015)... NEW YORK , June 24, 2015 ... Systems market, over the next six years. It contains ... affect the industry, along with their impact from the ... It also discusses the industry, market, and technology ... expected that the need of concerned authorities to efficiently ...
Breaking Biology News(10 mins):Latin America Biomedical Sensors Market Report 2015-2020 2@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2
... Researchers at Stanford,s Jasper Ridge Biological Preserve often encounter ... the occasional deer carcass covered with leaves. But few ... Now, images captured by remote wildlife cameras confirm ... regular visits to Stanford,s 1,189-acre preserve in the hills ...
... Congenital Dyserythropoietic Anemia type II (CDA II) is a rare ... erythropoiesis. What will surprise you is the fact that some ... back. A study led by the ENERCA member Prof. ... the University of Naples Federico II, analyzes two mutations (E109K ...
... -- An Illinois research team has succeeded in ... that simultaneously reduces atmospheric carbon dioxide and produces ... engineering professor Paul Kenis and his research group ... startup company, to produce a catalyst that improves ...
Cached Biology News:Learning to live in mountain lion country 2Study tracks mutations causing CDA II back to the Roman Empire 2Study tracks mutations causing CDA II back to the Roman Empire 3Ionic liquid catalyst helps turn emissions into fuel 2
Mouse monoclonal antibody raised against a partial recombinant PUM2. NCBI Entrez Gene ID = PUM2...
... The pWEB::TNC™ Deletion Cosmid Cloning Kit ... days, a complete and unbiased primary cosmid ... in making nested deletion sublibraries. High efficiency ... and highly reproducible kit protocols. First, genomic ...
... optically clear polystyrene with frosted labeling ... for cell counting. 100% integrity tested. ... new product number, created to easily ... no availability yet, please order under ...
Mouse monoclonal antibody raised against a partial recombinant AATK. NCBI Entrez Gene ID = AATK...
Biology Products: